{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:29:48Z","timestamp":1787567388659,"version":"build-2736575974"},"reference-count":114,"publisher":"eLife Sciences Publications, Ltd","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Cancer Institute","award":["R01CA262070"],"award-info":[{"award-number":["R01CA262070"]}]},{"award":["R01CA262070"],"award-info":[{"award-number":["R01CA262070"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"name":"National Cancer Institute","award":["R01CA285598"],"award-info":[{"award-number":["R01CA285598"]}]},{"award":["R01CA285598"],"award-info":[{"award-number":["R01CA285598"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"name":"National Cancer Institute","award":["R01CA288850"],"award-info":[{"award-number":["R01CA288850"]}]},{"award":["R01CA288850"],"award-info":[{"award-number":["R01CA288850"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014008","name":"Ovarian Cancer Research Alliance","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014008","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/05hg41718","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002956","name":"Foundation for Women\u2019s Cancer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002956","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006386","name":"Adenoid Cystic Carcinoma Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006386","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/04fafj987","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Torrey Coast Foundation"}],"content-domain":{"domain":["elifesciences.org"],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Therapeutic epigenetic modulation is currently being evaluated in the clinic to sensitize homologous recombination (HR)-proficient tumors to PARP inhibitors. To broaden its clinical applicability and identify more effective combination strategies, we conducted a drug screen combining PARP inhibitors with 74 well-characterized epigenetic modulators targeting five major classes of epigenetic enzymes. Notably, both type I PRMT inhibitors and PRMT5 inhibitors scored highly in combination efficacy and clinical prioritization. PRMT inhibition significantly enhanced PARP inhibitor-induced DNA damage in human HR-proficient ovarian and breast cancer cells. Mechanistically, PRMT suppression downregulates DNA damage repair genes and BRCAness-associated pathways, while also modulating intrinsic innate immune responses within cancer cells. Integrative analysis of large-scale genomic and functional datasets from TCGA and DepMap further supports PRMT1, PRMT4, and PRMT5 as promising therapeutic targets in oncology. Importantly, dual inhibition of PRMT1 and PRMT5 synergistically sensitizes tumors to PARP inhibitors. Collectively, our findings provide strong rationale for the clinical development of PRMT and PARP inhibitor combinations in HR-proficient ovarian and breast cancers.<\/jats:p>","DOI":"10.7554\/elife.99225","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T12:25:15Z","timestamp":1721219115000},"update-policy":"https:\/\/doi.org\/10.7554\/elife.99225","source":"Crossref","is-referenced-by-count":3,"title":["Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment"],"prefix":"10.7554","volume":"13","author":[{"given":"Youyou","family":"Zhang","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Center for Women\u2019s Health and Reproductive Medicine, University of Pennsylvania","place":["Philadelphia, United States"]},{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Obstetrics and Gynecology, University of Pennsylvania","place":["Philadelphia, United States"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"conceptualization","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Mu","family":"Xu","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Center for Women\u2019s Health and Reproductive Medicine, University of Pennsylvania","place":["Philadelphia, United States"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"conceptualization","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Jiao","family":"Yuan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Center for Women\u2019s Health and Reproductive Medicine, University of Pennsylvania","place":["Philadelphia, United States"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]},{"given":"Zhongyi","family":"Hu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Center for Women\u2019s Health and Reproductive Medicine, University of Pennsylvania","place":["Philadelphia, United States"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"data-curation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]},{"given":"Junjie","family":"Jiang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Center for Women\u2019s Health and Reproductive Medicine, University of Pennsylvania","place":["Philadelphia, United States"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Yanrong","family":"Sun","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Center for Women\u2019s Health and Reproductive Medicine, University of Pennsylvania","place":["Philadelphia, United States"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Center for Women\u2019s Health and Reproductive Medicine, University of Pennsylvania","place":["Philadelphia, United States"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Yuxin","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Center for Women\u2019s Health and Reproductive Medicine, University of Pennsylvania","place":["Philadelphia, United States"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"visualization","vocabulary":"credit"}]},{"given":"Bingwei","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Center for Women\u2019s Health and Reproductive Medicine, University of Pennsylvania","place":["Philadelphia, United States"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Jianfeng","family":"Shen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Center for Women\u2019s Health and Reproductive Medicine, University of Pennsylvania","place":["Philadelphia, United States"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"resources","vocabulary":"credit"}]},{"given":"Meixiao","family":"Long","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Hematology, Department of Internal Medicine, Ohio State University","place":["Columbus, United States"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"data-curation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]},{"given":"Yi","family":"Fan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Abramson Cancer Center, University of Pennsylvania","place":["Philadelphia, United States"]},{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Radiation Oncology, University of Pennsylvania","place":["Philadelphia, United States"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"data-curation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]},{"given":"Kathleen T","family":"Montone","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pathology and Laboratory Medicine, University of Pennsylvania","place":["Philadelphia, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janos","family":"Tanyi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Obstetrics and Gynecology, University of Pennsylvania","place":["Philadelphia, United States"]},{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Abramson Cancer Center, University of Pennsylvania","place":["Philadelphia, United States"]},{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Center for Gynecologic Cancer Immunotherapies, University of Pennsylvania","place":["Philadelphia, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah H","family":"Kim","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Obstetrics and Gynecology, University of Pennsylvania","place":["Philadelphia, United States"]},{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Abramson Cancer Center, University of Pennsylvania","place":["Philadelphia, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omid","family":"Tavana","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043cec594","id-type":"ROR","asserted-by":"publisher"}],"name":"Bioscience, Research and Early Development, Oncology R&D, AstraZeneca","place":["Waltham, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert H","family":"Vonderheide","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Abramson Cancer Center, University of Pennsylvania","place":["Philadelphia, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Man","family":"Chan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043cec594","id-type":"ROR","asserted-by":"publisher"}],"name":"Bioscience, Research and Early Development, Oncology R&D, AstraZeneca","place":["Waltham, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Domchek","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Abramson Cancer Center, University of Pennsylvania","place":["Philadelphia, United States"]},{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania","place":["Philadelphia, United States"]},{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Basser Center for BRCA, University of Pennsylvania","place":["Philadelphia, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1998-0611","authenticated-orcid":true,"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Center for Women\u2019s Health and Reproductive Medicine, University of Pennsylvania","place":["Philadelphia, United States"]},{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Obstetrics and Gynecology, University of Pennsylvania","place":["Philadelphia, United States"]},{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Abramson Cancer Center, University of Pennsylvania","place":["Philadelphia, United States"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"},{"role":"conceptualization","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3269-4356","authenticated-orcid":true,"given":"Xiaowen","family":"Hu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Center for Women\u2019s Health and Reproductive Medicine, University of Pennsylvania","place":["Philadelphia, United States"]},{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Obstetrics and Gynecology, University of Pennsylvania","place":["Philadelphia, United States"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"},{"role":"conceptualization","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]}],"member":"4374","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"22609","DOI":"10.1073\/pnas.1903765116","type":"journal-article","article-title":"DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation","volume":"116","author":"Abbotts","year":"2019","journal-title":"PNAS"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"19482","DOI":"10.1073\/pnas.0707828104","type":"journal-article","article-title":"HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination","volume":"104","author":"Adimoolam","year":"2007","journal-title":"PNAS"},{"key":"bib3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.1023","type":"journal-article","article-title":"A phase 1b\/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1\/2 mutations","volume":"40","author":"Aftimos","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1158\/1078-0432.CCR-21-3729","type":"journal-article","article-title":"Phase I clinical trial of DNA Methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed\/refractory acute myeloid Leukemia","volume":"28","author":"Baer","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1158\/1078-0432.CCR-21-3045","type":"journal-article","article-title":"Phase 1b clinical trial with alpelisib plus olaparib for patients with advanced triple-negative breast cancer","volume":"28","author":"Batalini","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1101\/gad.219899.113","type":"journal-article","article-title":"Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery","volume":"27","author":"Bezzi","year":"2013","journal-title":"Genes & Development"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","type":"journal-article","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.molcel.2016.11.003","type":"journal-article","article-title":"Arginine methylation: the coming of age","volume":"65","author":"Blanc","year":"2017","journal-title":"Molecular Cell"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1101\/gad.1279805","type":"journal-article","article-title":"Arginine methylation of MRE11 by PRMT1 is required for DNA damage checkpoint control","volume":"19","author":"Boisvert","year":"2005","journal-title":"Genes & Development"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","type":"journal-article","article-title":"Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nature Reviews. Cancer"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ccell.2017.08.018","type":"journal-article","article-title":"Coordinated splicing of regulatory detained introns within oncogenic transcripts creates an exploitable vulnerability in malignant glioma","volume":"32","author":"Braun","year":"2017","journal-title":"Cancer Cell"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","type":"journal-article","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas","year":"2012","journal-title":"Nature"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","type":"journal-article","article-title":"Cancer genome atlas research, N. integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1158\/2767-9764.CRC-23-0070","type":"journal-article","article-title":"PRMT5 inhibitors regulate DNA damage repair pathways in cancer cells and improve response to PARP inhibition and chemotherapies","volume":"3","author":"Carter","year":"2023","journal-title":"Cancer Research Communications"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ccell.2015.12.007","type":"journal-article","article-title":"Targeting aberrant epigenetic networks mediated by PRMT1 and KDM4C in acute myeloid leukemia","volume":"29","author":"Cheung","year":"2016","journal-title":"Cancer Cell"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1016\/j.celrep.2017.11.096","type":"journal-article","article-title":"PRMT5 is a critical regulator of breast cancer stem cell function via histone methylation and FOXP1 expression","volume":"21","author":"Chiang","year":"2017","journal-title":"Cell Reports"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","type":"journal-article","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Research"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.molcel.2017.01.019","type":"journal-article","article-title":"PRMT5-dependent methylation of the TIP60 coactivator RUVBL1 is a key regulator of homologous recombination","volume":"65","author":"Clarke","year":"2017","journal-title":"Molecular Cell"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nrc3399","type":"journal-article","article-title":"DNA repair dysregulation from cancer driver to therapeutic target","volume":"12","author":"Curtin","year":"2012","journal-title":"Nature Reviews. Cancer"},{"key":"bib20","doi-asserted-by":"publisher","DOI":"10.1038\/srep01311","type":"journal-article","article-title":"Loss of the major Type I arginine methyltransferase PRMT1 causes substrate scavenging by other PRMTs","volume":"3","author":"Dhar","year":"2013","journal-title":"Scientific Reports"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","type":"journal-article","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"bib22","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01037-1","type":"journal-article","article-title":"Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells","volume":"13","author":"Dominici","year":"2021","journal-title":"Clinical Epigenetics"},{"key":"bib23","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-21-P044","type":"journal-article","article-title":"Abstract P044: A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) brain penetrant inhibitor PRT811 in patients with advanced solid tumors, including recurrent high-grade gliomas","volume":"20","author":"Falchook","year":"2021","journal-title":"Molecular Cancer Therapeutics"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ccell.2019.05.014","type":"journal-article","article-title":"Anti-tumor activity of the Type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss","volume":"36","author":"Fedoriw","year":"2019","journal-title":"Cancer Cell"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ccell.2019.07.003","type":"journal-article","article-title":"Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation","volume":"36","author":"Fong","year":"2019","journal-title":"Cancer Cell"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1214271","type":"journal-article","article-title":"ERCC1 isoform expression and DNA repair in non-small-cell lung cancer","volume":"368","author":"Friboulet","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1021\/acs.chemrev.5b00003","type":"journal-article","article-title":"Chemical biology of protein arginine modifications in epigenetic regulation","volume":"115","author":"Fuhrmann","year":"2015","journal-title":"Chemical Reviews"},{"key":"bib28","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100034","type":"journal-article","article-title":"Single-arm, open label prospective trial to assess prediction of the role of ERCC1\/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy","volume":"6","author":"Ganzinelli","year":"2021","journal-title":"ESMO Open"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1093\/nar\/gkz200","type":"journal-article","article-title":"PRMT1 loss sensitizes cells to PRMT5 inhibition","volume":"47","author":"Gao","year":"2019","journal-title":"Nucleic Acids Research"},{"key":"bib30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28002-y","type":"journal-article","article-title":"Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing","volume":"8","author":"Gerhart","year":"2018","journal-title":"Scientific Reports"},{"key":"bib31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24798-y","type":"journal-article","article-title":"PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma","volume":"12","author":"Giuliani","year":"2021","journal-title":"Nature Communications"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"33009","DOI":"10.1074\/jbc.M704349200","type":"journal-article","article-title":"Alternative splicing yields protein arginine methyltransferase 1 isoforms with distinct activity, substrate specificity, and subcellular localization","volume":"282","author":"Goulet","year":"2007","journal-title":"The Journal of Biological Chemistry"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","type":"journal-article","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nature Reviews. Cancer"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41580-019-0155-x","type":"journal-article","article-title":"The regulation, functions and clinical relevance of arginine methylation","volume":"20","author":"Guccione","year":"2019","journal-title":"Nature Reviews. Molecular Cell Biology"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/nchembio.422","type":"journal-article","article-title":"Methylation of FEN1 suppresses nearby phosphorylation and facilitates PCNA binding","volume":"6","author":"Guo","year":"2010","journal-title":"Nature Chemical Biology"},{"key":"bib36","doi-asserted-by":"publisher","DOI":"10.1038\/srep10475","type":"journal-article","article-title":"Arginine methylation of hnRNPUL1 regulates interaction with NBS1 and recruitment to sites of DNA damage","volume":"5","author":"Gurunathan","year":"2015","journal-title":"Scientific Reports"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1016\/j.celrep.2018.08.002","type":"journal-article","article-title":"PRMT5 regulates DNA repair by controlling the alternative splicing of histone-modifying enzymes","volume":"24","author":"Hamard","year":"2018","journal-title":"Cell Reports"},{"key":"bib38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146987","type":"journal-article","article-title":"Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes","volume":"138","author":"Haque","year":"2021","journal-title":"Blood"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1093\/nar\/gkq1264","type":"journal-article","article-title":"A role for the arginine methylation of Rad9 in checkpoint control and cellular sensitivity to DNA damage","volume":"39","author":"He","year":"2011","journal-title":"Nucleic Acids Research"},{"key":"bib40","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201899184","type":"journal-article","article-title":"Local activation of mammalian separase in interphase promotes double-strand break repair and prevents oncogenic transformation","volume":"37","author":"Hellmuth","year":"2018","journal-title":"The EMBO Journal"},{"key":"bib41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08554-x","type":"journal-article","article-title":"Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment","volume":"10","author":"Hu","year":"2019","journal-title":"Nature Communications"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/s43018-021-00282-w","type":"journal-article","article-title":"The cancer surfaceome atlas integrates genomic, functional and drug response data to identify actionable targets","volume":"2","author":"Hu","year":"2021","journal-title":"Nature Cancer"},{"key":"bib43","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","type":"journal-article","article-title":"PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition","volume":"2","author":"Ibrahim","year":"2012","journal-title":"Cancer Discovery"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ccell.2017.12.009","type":"journal-article","article-title":"EWS\/FLI confers tumor cell synthetic lethality to CDK12 inhibition in ewing sarcoma","volume":"33","author":"Iniguez","year":"2018","journal-title":"Cancer Cell"},{"key":"bib45","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.molmed.2019.05.007","type":"journal-article","article-title":"PRMTs and arginine methylation: cancer\u2019s best-kept secret?","volume":"25","author":"Jarrold","year":"2019","journal-title":"Trends in Molecular Medicine"},{"key":"bib46","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110400","type":"journal-article","article-title":"Systematic illumination of druggable genes in cancer genomes","volume":"38","author":"Jiang","year":"2022","journal-title":"Cell Reports"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.celrep.2016.10.077","type":"journal-article","article-title":"CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer","volume":"17","author":"Johnson","year":"2016","journal-title":"Cell Reports"},{"key":"bib48","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/2159-8290.CD-11-0336","type":"journal-article","article-title":"Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer","volume":"2","author":"Juvekar","year":"2012","journal-title":"Cancer Discovery"},{"key":"bib49","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2020.12.010","type":"journal-article","article-title":"MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage","volume":"39","author":"Kalev","year":"2021","journal-title":"Cancer Cell"},{"key":"bib50","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1016\/j.celrep.2017.11.095","type":"journal-article","article-title":"BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer","volume":"21","author":"Karakashev","year":"2017","journal-title":"Cell Reports"},{"key":"bib51","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz5683","type":"journal-article","article-title":"PRMT5 control of cGAS\/STING and NLRC5 pathways defines melanoma response to antitumor immunity","volume":"12","author":"Kim","year":"2020","journal-title":"Science Translational Medicine"},{"key":"bib52","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","type":"journal-article","article-title":"Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas","volume":"23","author":"Knijnenburg","year":"2018","journal-title":"Cell Reports"},{"key":"bib53","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature14351","type":"journal-article","article-title":"MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis","volume":"523","author":"Koh","year":"2015","journal-title":"Nature"},{"key":"bib54","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ygyno.2014.03.007","type":"journal-article","article-title":"Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer","volume":"133","author":"Konstantinopoulos","year":"2014","journal-title":"Gynecologic Oncology"},{"key":"bib55","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","type":"journal-article","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discovery"},{"key":"bib56","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/S1470-2045(18)30905-7","type":"journal-article","article-title":"Olaparib and \u03b1-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial","volume":"20","author":"Konstantinopoulos","year":"2019","journal-title":"The Lancet. Oncology"},{"key":"bib57","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1126\/science.aad5214","type":"journal-article","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"key":"bib58","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","type":"journal-article","article-title":"The cytosolic DNA-sensing cGAS-STING pathway in cancer","volume":"10","author":"Kwon","year":"2020","journal-title":"Cancer Discovery"},{"key":"bib59","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1200\/JCO.2016.68.1841","type":"journal-article","article-title":"Randomized prospective biomarker trial of ERCC1 for comparing platinum and nonplatinum therapy in advanced non-small-cell lung cancer: ERCC1 Trial (ET)","volume":"35","author":"Lee","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"bib60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21963-1","type":"journal-article","article-title":"Profiling PRMT methylome reveals roles of hnRNPA1 arginine methylation in RNA splicing and cell growth","volume":"12","author":"Li","year":"1946","journal-title":"Nature Communications"},{"key":"bib61","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101326","type":"journal-article","article-title":"PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition","volume":"4","author":"Li","year":"2023","journal-title":"Cell Reports. Medicine"},{"key":"bib62","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","type":"journal-article","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Systems"},{"key":"bib63","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add8928","type":"journal-article","article-title":"Arginine methylation of BRD4 by PRMT2\/4 governs transcription and DNA repair","volume":"8","author":"Liu","year":"2022","journal-title":"Science Advances"},{"key":"bib64","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc.2015.21","type":"journal-article","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nature Reviews. Cancer"},{"key":"bib65","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","type":"journal-article","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"bib66","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1007\/s00018-019-03140-2","type":"journal-article","article-title":"Cellular consequences of arginine methylation","volume":"76","author":"Lorton","year":"2019","journal-title":"Cellular and Molecular Life Sciences"},{"key":"bib67","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","type":"journal-article","article-title":"MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Reports"},{"key":"bib68","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1126\/science.aad5944","type":"journal-article","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"key":"bib69","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-21-P039","type":"journal-article","article-title":"Abstract P039: A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) inhibitor PRT543 in patients with advanced solid tumors and lymphoma","volume":"20","author":"McKean","year":"2021","journal-title":"Molecular Cancer Therapeutics"},{"key":"bib70","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.celrep.2020.01.054","type":"journal-article","article-title":"Symmetric arginine dimethylation is selectively required for mRNA splicing and the initiation of Type I and Type III interferon signaling","volume":"30","author":"Metz","year":"2020","journal-title":"Cell Reports"},{"key":"bib71","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/nsmb.2209","type":"journal-article","article-title":"Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance","volume":"19","author":"Migliori","year":"2012","journal-title":"Nature Structural & Molecular Biology"},{"key":"bib72","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1158\/1078-0432.CCR-15-1772","type":"journal-article","article-title":"mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer","volume":"22","author":"Mo","year":"2016","journal-title":"Clinical Cancer Research"},{"key":"bib73","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/00031305.1948.10483405","type":"journal-article","article-title":"Questions and answers","volume":"2","author":"Mosteller","year":"1948","journal-title":"The American Statistician"},{"key":"bib74","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.celrep.2019.12.061","type":"journal-article","article-title":"PRMT1 is recruited via DNA-PK to chromatin where it sustains the senescence-associated secretory phenotype in response to cisplatin","volume":"30","author":"Musiani","year":"2020","journal-title":"Cell Reports"},{"key":"bib75","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.ccell.2016.09.002","type":"journal-article","article-title":"Enhancing the cytotoxic effects of PARP inhibitors with DNA demethylating agents - a potential therapy for cancer","volume":"30","author":"Muvarak","year":"2016","journal-title":"Cancer Cell"},{"key":"bib76","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11260-z","type":"journal-article","article-title":"Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer","volume":"23","author":"O\u2019Brien","year":"2023","journal-title":"BMC Cancer"},{"key":"bib77","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","type":"journal-article","article-title":"Targeting the DNA damage response in cancer","volume":"60","author":"O\u2019Connor","year":"2015","journal-title":"Molecular Cell"},{"key":"bib78","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1056\/NEJMoa060570","type":"journal-article","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"The New England Journal of Medicine"},{"key":"bib79","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1158\/2159-8290.CD-20-0026","type":"journal-article","article-title":"PRMT5 inhibition modulates E2F1 methylation and gene-regulatory networks leading to therapeutic efficacy in JAK2V617F-Mutant MPN","volume":"10","author":"Pastore","year":"2020","journal-title":"Cancer Discovery"},{"key":"bib80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150938","type":"journal-article","article-title":"A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) inhibitor PRT543 in patients with myeloid malignancies","volume":"138","author":"Patel","year":"2021","journal-title":"Blood"},{"key":"bib81","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nrc3891","type":"journal-article","article-title":"Therapeutic opportunities within the DNA damage response","volume":"15","author":"Pearl","year":"2015","journal-title":"Nature Reviews. Cancer"},{"key":"bib82","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","type":"journal-article","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pili\u00e9","year":"2019","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"bib83","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf9246","type":"journal-article","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Science Translational Medicine"},{"key":"bib84","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.1038\/onc.2013.311","type":"journal-article","article-title":"A high-throughput screen identifies PARP1\/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer","volume":"32","author":"Postel-Vinay","year":"2013","journal-title":"Oncogene"},{"key":"bib85","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/s41594-019-0313-z","type":"journal-article","article-title":"PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia","volume":"26","author":"Radzisheuskaya","year":"2019","journal-title":"Nature Structural & Molecular Biology"},{"key":"bib86","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/emboj\/cdg082","type":"journal-article","article-title":"p53 is a chromatin accessibility factor for nucleotide excision repair of DNA damage","volume":"22","author":"Rubbi","year":"2003","journal-title":"The EMBO Journal"},{"key":"bib87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21204-5","type":"journal-article","article-title":"PRMT5 inhibition disrupts splicing and stemness in glioblastoma","volume":"12","author":"Sachamitr","year":"2021","journal-title":"Nature Communications"},{"key":"bib88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26413-6","type":"journal-article","article-title":"Arginine methylation and ubiquitylation crosstalk controls DNA end-resection and homologous recombination repair","volume":"12","author":"Sanchez-Bailon","year":"2021","journal-title":"Nature Communications"},{"key":"bib89","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1200\/JCO.2014.58.8848","type":"journal-article","article-title":"Poly (ADP-ribose) polymerase inhibitors: recent advances and future development","volume":"33","author":"Scott","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"bib90","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107884","type":"journal-article","article-title":"Systematic characterization of recurrent genomic alterations in cyclin-dependent kinases reveals potential therapeutic strategies for cancer treatment","volume":"32","author":"Shan","year":"2020","journal-title":"Cell Reports"},{"key":"bib91","doi-asserted-by":"publisher","first-page":"E5593","DOI":"10.1073\/pnas.1419161111","type":"journal-article","article-title":"rMATS: Robust and flexible detection of differential alternative splicing from replicate RNA-Seq data","volume":"111","author":"Shen","year":"2014","journal-title":"PNAS"},{"key":"bib92","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz244","type":"journal-article","article-title":"METEOR-1: a phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours","volume":"30","author":"Siu","year":"2019","journal-title":"Annals of Oncology"},{"key":"bib93","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ccell.2019.06.004","type":"journal-article","article-title":"M-TAP dance: targeting PRMT1 and PRMT5 family members to push cancer cells over the edge","volume":"36","author":"Srour","year":"2019","journal-title":"Cancer Cell"},{"key":"bib94","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal5148","type":"journal-article","article-title":"Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers","volume":"9","author":"Sun","year":"2017","journal-title":"Science Translational Medicine"},{"key":"bib95","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccell.2018.01.019","type":"journal-article","article-title":"BRD4 inhibition is synthetic lethal with PARP inhibitors through the induction of homologous recombination deficiency","volume":"33","author":"Sun","year":"2018","journal-title":"Cancer Cell"},{"key":"bib96","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1016\/j.celrep.2019.02.001","type":"journal-article","article-title":"PRMT5 modulates splicing for genome integrity and preserves proteostasis of hematopoietic stem cells","volume":"26","author":"Tan","year":"2019","journal-title":"Cell Reports"},{"key":"bib97","doi-asserted-by":"publisher","first-page":"7723","DOI":"10.1074\/jbc.275.11.7723","type":"journal-article","article-title":"PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells","volume":"275","author":"Tang","year":"2000","journal-title":"The Journal of Biological Chemistry"},{"key":"bib98","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.molcel.2013.05.021","type":"journal-article","article-title":"Defining the RGG\/RG motif","volume":"50","author":"Thandapani","year":"2013","journal-title":"Molecular Cell"},{"key":"bib99","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03817-5","type":"journal-article","article-title":"GFI1 facilitates efficient DNA repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1","volume":"9","author":"Vadnais","year":"2018","journal-title":"Nature Communications"},{"key":"bib100","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.651","type":"journal-article","article-title":"537MO First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers","volume":"31","author":"Villar","year":"2020","journal-title":"Annals of Oncology"},{"key":"bib101","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nbt.3772","type":"journal-article","article-title":"Toil enables reproducible, open source, big biomedical data analyses","volume":"35","author":"Vivian","year":"2017","journal-title":"Nature Biotechnology"},{"key":"bib102","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1093\/bioinformatics\/btx128","type":"journal-article","article-title":"rMATS-DVR: rMATS discovery of differential variants in RNA","volume":"33","author":"Wang","year":"2017","journal-title":"Bioinformatics"},{"key":"bib103","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130337","type":"journal-article","article-title":"A Phase I\/II study to investigate the safety and clinical activity of the protein arginine methyltransferase 5 inhibitor GSK3326595 in subjects with myelodysplastic syndrome and acute myeloid leukemia","volume":"134","author":"Watts","year":"2019","journal-title":"Blood"},{"key":"bib104","doi-asserted-by":"publisher","first-page":"28068","DOI":"10.1073\/pnas.2009899117","type":"journal-article","article-title":"Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells","volume":"117","author":"Wei","year":"2020","journal-title":"PNAS"},{"key":"bib105","doi-asserted-by":"publisher","first-page":"6354","DOI":"10.1158\/1078-0432.CCR-21-1656","type":"journal-article","article-title":"Phase Ib dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple-negative breast, and ovarian cancer","volume":"27","author":"Westin","year":"2021","journal-title":"Clinical Cancer Research"},{"key":"bib106","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1126\/science.1056154","type":"journal-article","article-title":"Human DNA repair genes","volume":"291","author":"Wood","year":"2001","journal-title":"Science"},{"key":"bib107","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41573-021-00159-8","type":"journal-article","article-title":"Protein arginine methylation: from enigmatic functions to therapeutic targeting","volume":"20","author":"Wu","year":"2021","journal-title":"Nature Reviews. Drug Discovery"},{"key":"bib108","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/s41589-022-01024-4","type":"journal-article","article-title":"PRMT inhibition induces a viral mimicry response in triple-negative breast cancer","volume":"18","author":"Wu","year":"2022","journal-title":"Nature Chemical Biology"},{"key":"bib109","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nature21671","type":"journal-article","article-title":"RNA m6A methylation regulates the ultraviolet-induced DNA damage response","volume":"543","author":"Xiang","year":"2017","journal-title":"Nature"},{"key":"bib110","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal1645","type":"journal-article","article-title":"Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition","volume":"9","author":"Yang","year":"2017","journal-title":"Science Translational Medicine"},{"key":"bib111","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1158\/2159-8290.CD-20-0163","type":"journal-article","article-title":"Phase I trial of the PARP inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1\/2- and Non-BRCA1\/2-mutant cancers","volume":"10","author":"Yap","year":"2020","journal-title":"Cancer Discovery"},{"key":"bib112","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1128\/MCB.00042-09","type":"journal-article","article-title":"A mouse PRMT1 null allele defines an essential role for arginine methylation in genome maintenance and cell proliferation","volume":"29","author":"Yu","year":"2009","journal-title":"Molecular and Cellular Biology"},{"key":"bib113","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/cr.2011.128","type":"journal-article","article-title":"The MRE11 GAR motif regulates DNA double-strand break processing and ATR activation","volume":"22","author":"Yu","year":"2012","journal-title":"Cell Research"},{"key":"dataset1","type":"dataset","article-title":"Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment","volume-title":"NCBI BioProject","author":"Zhang","year":"2023","unstructured":"Zhang Y, Hu Z, Zhang L, Hu X. 2023. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. NCBI BioProject. https:\/\/www.ncbi.nlm.nih.gov\/bioproject\/PRJNA945030. PRJNA945030."}],"container-title":["eLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.elifesciences.org\/articles\/99225\/elife-99225-v1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cdn.elifesciences.org\/articles\/99225\/elife-99225-v1.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/elifesciences.org\/articles\/99225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:08:27Z","timestamp":1787562507000},"score":1,"resource":{"primary":{"URL":"https:\/\/elifesciences.org\/articles\/99225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":114,"alternative-id":["10.7554\/eLife.99225"],"URL":"https:\/\/doi.org\/10.7554\/elife.99225","archive":["CLOCKSS"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.05.21.595159","asserted-by":"subject"}],"is-same-as":[{"id-type":"doi","id":"10.7554\/eLife.99225.4","asserted-by":"subject"}],"is-version-of":[{"id-type":"doi","id":"10.7554\/eLife.99225.1","asserted-by":"subject"},{"id-type":"doi","id":"10.7554\/eLife.99225.2","asserted-by":"subject"},{"id-type":"doi","id":"10.7554\/eLife.99225.3","asserted-by":"subject"}],"is-supplemented-by":[{"id-type":"accession","id":"PRJNA945030","asserted-by":"subject"}]},"ISSN":["2050-084X"],"issn-type":[{"value":"2050-084X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"single anonymised","name":"peer_review_transparency","label":"Peer review transparency","group":{"name":"peer_review_taxonomy"}},{"value":"other reviewer(s), editor","name":"peer_review_interaction","label":"Peer review interaction","group":{"name":"peer_review_taxonomy"}},{"value":"review summaries, review reports, author\/editor communication, reviewer identities reviewer opt in, editor identities","name":"peer_review_published","label":"Peer review published","group":{"name":"peer_review_taxonomy"}},{"value":"open (sign in with ORCID iD required)","name":"post_publication_commenting","label":"Post publication commenting","group":{"name":"post_publication_commenting"}}],"article-number":"RP99225"}}